-
Je něco špatně v tomto záznamu ?
Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis
J. Radocha, R. Hájek, L. Brožová, L. Pour, I. Špička, J. Minařík, E. Gregora, A. Jungová, T. Jelínek, A. Heindorfer, M. Sýkora, V. Maisnar,
Jazyk angličtina Země Německo
Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie
NLK
Medline Complete (EBSCOhost)
od 2000-01-01
Springer Nature OA/Free Journals
od 1955-03-01
- MeSH
- lidé MeSH
- míra přežití MeSH
- mnohočetný myelom mortalita terapie MeSH
- přežití bez známek nemoci MeSH
- registrace * MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- věkové faktory MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65 years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65 years with symptomatic myeloma were included. The four major parameters with impact on survival were identified: male gender, age > 75, creatinine > 152 μmol/L, and ECOG performance status 2-4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3-4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8-81.7) for good, 51.0 (44.1-57.8) for intermediate good, 32.2 (26.2-38.2) for intermediate poor, and 18.9 (15.1-22.7) for poor. The differences in OS were statistically significant (p < 0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09-1.84) for intermediate good, 2.58 (2.00-3.33) for intermediate poor, and 3.88 (2.94-5.10) for poor. Time to progression showed medians (months) 20.5 (17.4-62.4) for good, 19.3 (17.0-21.7) for intermediate good, 19.6 (16.2-23.0) for intermediate poor, and 13.0 (10.8-15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65 years.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012051
- 003
- CZ-PrNML
- 005
- 20211213144528.0
- 007
- ta
- 008
- 190405s2019 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00277-018-3568-2 $2 doi
- 035 __
- $a (PubMed)30539278
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Radocha, J $u 4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Králové, Czech Republic. jakub.radocha@centrum.cz. Czech Myeloma Group, Brno, Czech Republic. jakub.radocha@centrum.cz.
- 245 10
- $a Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis / $c J. Radocha, R. Hájek, L. Brožová, L. Pour, I. Špička, J. Minařík, E. Gregora, A. Jungová, T. Jelínek, A. Heindorfer, M. Sýkora, V. Maisnar,
- 520 9_
- $a The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65 years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65 years with symptomatic myeloma were included. The four major parameters with impact on survival were identified: male gender, age > 75, creatinine > 152 μmol/L, and ECOG performance status 2-4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3-4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8-81.7) for good, 51.0 (44.1-57.8) for intermediate good, 32.2 (26.2-38.2) for intermediate poor, and 18.9 (15.1-22.7) for poor. The differences in OS were statistically significant (p < 0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09-1.84) for intermediate good, 2.58 (2.00-3.33) for intermediate poor, and 3.88 (2.94-5.10) for poor. Time to progression showed medians (months) 20.5 (17.4-62.4) for good, 19.3 (17.0-21.7) for intermediate good, 19.6 (16.2-23.0) for intermediate poor, and 13.0 (10.8-15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65 years.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mnohočetný myelom $x mortalita $x terapie $7 D009101
- 650 12
- $a registrace $7 D012042
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Hájek, R $u Czech Myeloma Group, Brno, Czech Republic. Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Brožová, L $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Pour, L $u Czech Myeloma Group, Brno, Czech Republic. Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine Masaryk Universtiy, University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Špička, I $u Czech Myeloma Group, Brno, Czech Republic. 1st Medical Department - Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic.
- 700 1_
- $a Minařík, J $u Czech Myeloma Group, Brno, Czech Republic. Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Gregora, E $u Czech Myeloma Group, Brno, Czech Republic. Department of Internal Medicine and Hematology, 3rd Faculty of Medicine, Charles University, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
- 700 1_
- $a Jungová, A $u Czech Myeloma Group, Brno, Czech Republic. Hematology and Oncology Department, Charles University Hospital Pilsen, Prague, Czech Republic.
- 700 1_
- $a Jelínek, T $u Czech Myeloma Group, Brno, Czech Republic. Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Heindorfer, Adriana $u Czech Myeloma Group, Brno, Czech Republic. Department of Clinical Hematology, Hospital Liberec, Liberec, Czech Republic. $7 xx0267376
- 700 1_
- $a Sýkora, M $u Czech Myeloma Group, Brno, Czech Republic. Department of Clinical Hematology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic.
- 700 1_
- $a Maisnar, V $u 4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Králové, Czech Republic. Czech Myeloma Group, Brno, Czech Republic.
- 773 0_
- $w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 98, č. 4 (2019), s. 951-962
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30539278 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20211213144527 $b ABA008
- 999 __
- $a ok $b bmc $g 1391361 $s 1050356
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 98 $c 4 $d 951-962 $e 20181211 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
- LZP __
- $a Pubmed-20190405
